Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomitapide in Paediatric HoFH
NCT04681170Phase 3Completed
- Sponsor
- Amryt Pharma
- Start
- Dec 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label trial of lomitapide in homozygous familial hypercholesterolemia (HoFH) (3 arms), sponsored by Amryt Pharma. Primary endpoint: Percent Change in Low-density Lipoprotein Cholesterol at 24 weeks. Started Dec 2020; status: completed.
02
Drugs
lomitapide
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT04681170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04681170.